secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2026-08-06T20:10:49+00:00
Accession:  0001193125-26-338008
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q2 net loss narrows to $23M; cash runway through 2027; AL137 IND targeted Q1 2027
--------------------------------------------------------------------------------

- Net loss of $23.0M ($0.21/share) vs $30.5M ($0.30/share) in Q2 2025; revenue $3.3M (down from $7.9M).
- Cash, equivalents, and investments $172.8M as of June 30, 2026; runway at least through 2027.
- Lead ABC-enabled anti-Aβ antibody AL137 selected; IND submission targeted Q1 2027 with first-in-human dosing in Australia by April 2027.
- Tau siRNA program AL064/AL164 advancing into IND-enabling studies; AL050 GCase ERT for PD in preclinical development.
- R&D expenses fell to $19.5M from $27.6M; G&A expenses fell to $8.3M from $14.4M, driven by workforce reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/0001193125-26-338008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000119312526338008/alec-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer